TRS-005 is an anti- CD20 ADC, formed by conjugating an anti-CD20 monoclonal antibody to MMAE via a Val-Cit linker. TRS-005 targets CD20-positive tumor cells and delivers MMAE into cells through receptor-mediated endocytosis. TRS-005 can be used for research on relapsed/refractory B-cell non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma ) [1].
References:
[1]. Shi Y, et al. The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study[J]. 2024.
References:
[1]. Shi Y, et al. The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study[J]. 2024.